A Multicenter Phase 2, Open Label Study of Intratumoral Tavo Plus Electroporation in Combination With Intravenous Pembrolizumab in Patients With Stage III/IV Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment (Keynote 695)

Investigator: Eric Bernicker, MD

Study Coordinator: Daniel (cancer) Le (cancer)

Status: Active

ClinicalTrials.gov Number: N/A

Phone: 346.238.5655

Protocol Number: Pro000022852

Description

Keynote 695 will be a Phase 2 study of intratumoral tavokinogene telseplasmid (tavo; pIL-12) Electroporation (EP) plus IV Pembrolizumab. Eligible patients will be those with pathological diagnosis of unresectable or metastatic melanoma who are progressing or have progressed on pembrolizumab or nivolumab.
More to Explore
Search Clinical Trials
Join a Clinical Trial
Clinical Research Support Services for Investigators
Weill Cornell Medical College Clinical Trials